Enalapril Maleate

According to the FDA label: Enalapril maleate is an angiotensin-converting enzyme inhibitor indicated for: treatment of hypertension in adults and children older than one month, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) treatment of symptomatic heart failure.

54,795 adverse event reports submitted to the FDA (2002–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Enalapril Maleate in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Enalapril Maleate adverse event reports by reporter sex
SexReports
Female25,980
Male25,797
Unknown102

By Age Group

View age group data as a table
Enalapril Maleate adverse event reports by reporter age group
Age groupReports
0-172,048
18-341,212
35-493,426
50-6411,366
65-7410,998
75+11,986

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Enalapril Maleate. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Enalapril Maleate adverse event reports by reported outcome
OutcomeReports
Hospitalization26,514
Other Serious25,652
Non-Serious8,617
Death5,944
Life-Threatening4,252
Disability1,654

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Enalapril Maleate. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Enalapril Maleate adverse event reports by year
YearReports
20022
20033
20041,156
20051,434
20061,358
20071,271
20081,569
20091,859
20102,312
20112,754
20122,964
20132,582
20143,064
20153,164
20163,114
20173,217
20184,243
20193,802
20203,250
20212,720
20222,345
20232,400
20241,998
20251,816
2026 (partial)398

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Enalapril Maleate

In FDA adverse event reports that mention Enalapril Maleate, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026